Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | CETP | P11597 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.41 |
| ▸ | HTR3A | P46098 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3243535 | 0.86 | MAPT (0.41) | MAPTLMNACETPGAAKDM4E | |
| SCHEMBL1124075 | 0.85 | MAPT (0.56) | MAPTLMNACETPGAANPSR1 | |
| SCHEMBL3244102 | 0.84 | CASP1 (0.55) | MAPTLMNAGAANPSR1KDM4E | |
| SCHEMBL6354636 | 0.81 | KDM4E (0.51) | MAPTLMNANPSR1KDM4EHTT | |
| SCHEMBL1123878 | 0.79 | KMT2A (0.52) | MAPTLMNAGAANPSR1KDM4E | |
| SCHEMBL31647326 | 0.77 | MAPT (0.45) | MAPTLMNACETPGAANPSR1 | |
| SCHEMBL8104640 | 0.76 | GALR2 (0.41) | MAPTLMNACETPNPSR1KDM4E | |
| SCHEMBL6394558 | 0.74 | RBP4 (0.50) | MAPTLMNACETPNPSR1KDM4E | |
| SCHEMBL8403164 | 0.73 | HTT (0.42) | MAPTLMNAGAAHTTDCTPP1 | |
| SCHEMBL6395978 | 0.72 | RBP4 (0.54) | MAPTKDM4EHTTRAB9ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8563715-B2 | Pyrimidine derivative having cell protecting effect and uses thereof | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2013-10-22 | — | — | US | disclosed |
| US-8563715-B2 | Pyrimidine derivative having cell protecting effect and uses thereof | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2013-10-22 | — | — | US | disclosed |
| EP-2284160-B1 | PYRIMIDINE DERIVATIVE HAVING CELL-PROTECTING ACTIVITY AND USE THEREOF | ZENYAKU KOGYO KK (JP) | 2013-05-15 | — | — | EP | disclosed |
| US-20110152519-A1 | PYRIMIDINE DERIVATIVE HAVING CELL PROTECTING EFFECT AND USES THEREOF | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2011-06-23 | — | — | US | disclosed |
| US-20110152519-A1 | PYRIMIDINE DERIVATIVE HAVING CELL PROTECTING EFFECT AND USES THEREOF | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2011-06-23 | — | — | US | disclosed |
| CN-102046609-A | pyrimidine derivative having cell-protective effect and use thereof | ZENYAKU KOGYO KK | 2011-05-04 | — | — | CN | disclosed |
| EP-2284160-A1 | PYRIMIDINE DERIVATIVE HAVING CELL-PROTECTING ACTIVITY AND USE THEREOF | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2011-02-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152519-A1 | PYRIMIDINE DERIVATIVE HAVING CELL PROTECTING EFFECT AND USES THEREOF | CASP3, DPYD, CASP1 | MAPT 350/4885LMNA 1872/4885CETP 4132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.